Schultz NH, Glosli H, Bjørnsen S, Holme PA (2021)
The effect of emicizumab and bypassing agents in patients with hemophilia - An in vitro study
Res Pract Thromb Haemost, 5 (5), e12561
DOI 10.1002/rth2.12561, PubMed 34263107

Fernandez-Checa JC, Bagnaninchi P, Ye H, Sancho-Bru P, Falcon-Perez JM, Royo F, Garcia-Ruiz C, Konu O, Miranda J, Lunov O, Dejneka A, Elfick A, McDonald A, Sullivan GJ, Aithal G, Lucena MI, Andrade RJ, Fromenty B, Krannendonk M, Cubero FJ, Nelson LJ (2021)
ADVANCED PRECLINICAL MODELS FOR EVALUATION OF DRUG INDUCED LIVER INJURY - CONSENSUS STATEMENT BY THE EUROPEAN DRUG-INDUCED LIVER INJURY NETWORK [PRO-EURO-DILI-NET]
J Hepatol (in press)
DOI 10.1016/j.jhep.2021.06.021, PubMed 34171436

Kristensen VA, Opheim R, Perminow G, Huppertz-Hauss G, Detlie TE, Lund C, Andersen S, Olsen BC, Johansen I, Medhus AW, Vatn S, Brackmann S, Olbjørn C, Rove J, Henriksen M, Løvlund EE, Bengtson MB, Aabrekk TB, Tønnessen T, Vikskjold FB, Yassin H, Frigstad SO, Hasund A, Høie O, Schmidt K et al. (2021)
Inflammatory bowel disease in South-Eastern Norway III (IBSEN III): a new population-based inception cohort study from South-Eastern Norway
Scand J Gastroenterol, 56 (8), 899-905
DOI 10.1080/00365521.2021.1922746, PubMed 34154494